A compound of formula I where: R 1 is halo, alkyl, cycloalkyl, alkoxy, oxazolidinonyl, dioxothiazinyl, R 5 R 6 N, piperidinonyl substituted with 1 substituent, pyrrolyl substituted with 1 substituent, or phenyl where said phenyl is substituted with 1-2 substituents selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, carboxy, and CONR 7 R 8, and where said phenyl is also substituted with 0-2 halo, alkyl, alkoxy, pyridinyl, phenyl or halophenyl substituents; R 2 is hydrogen, halo, alkyl, cycloalkyl, alkoxy, or R 5 R 6 N; R 3 is CONR 11 R 12; R 4 is phenyl substituted with 0-2 halo; R 5 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, benzyl, alkylcarbonyl, haloalkylcarbonyl, phenylcarbonyl, (alkoxyphenyl)carbonyl, alkylsulfonyl, phenylsulfonyl, (alkoxyphenyl)sulfonyl or (haloalkoxyphenyl)sulfonyl; R 6 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl; or R 5 and R 6 taken together with the nitrogen to which they are attached is oxazolidinonyl or dioxothiazinyl; R 7 is hydrogen, alkyl, R 8 is hydrogen or alkyl; R 9 is hydrogen or alkyl; R 10 is hydrogen or alkyl; or R 9 and R 10 taken together is ethylene, propylene, butylene, or pentylene; R 11 is hydrogen or alkyl; R 12 is hydrogen or alkyl; or R 11 and R 12 taken together with the nitrogen to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl; R 13 is hydrogen or alkyl; R 14 is hydrogen or alkyl; or R 13 and R 14 taken together with the nitrogen to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl; R 15 is alkyl or cycloalkyl; R 16 is hydrogen, halo, alkyl, or alkoxy; R 17 is hydrogen, halo, alkyl, or alkoxy; and Ar 1 is isoxazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, or phenyl, and is substituted with 0-1 halo, alkyl, or phenyl substituents; or a pharmaceutically acceptable salt thereof. R 1 is halo, alkyl, cycloalkyl, alkoxy, oxazolidinonyl, dioxothiazinyl, R 5 R 6 N, piperidinonyl substituted with 1 substituent, pyrrolyl substituted with 1 substituent, or phenyl where said phenyl is substituted with 1-2 substituents selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, carboxy, and CONR 7 R 8, and where said phenyl is also substituted with 0-2 halo, alkyl, alkoxy, pyridinyl, phenyl or halophenyl substituents; R 2 is hydrogen, halo, alkyl, cycloalkyl, alkoxy, or R 5 R 6 N; R 3 is CONR 11 R 12; R 4 is phenyl substituted with 0-2 halo; R 5 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, benzyl, alkylcarbonyl, haloalkylcarbonyl, phenylcarbonyl, (alkoxyphenyl)carbonyl, alkylsulfonyl, phenylsulfonyl, (alkoxyphenyl)sulfonyl or (haloalkoxyphenyl)sulfonyl; R 6 is hydrogen, alkyl, hydroxyalkyl, or alkoxyalkyl; or R 5 and R 6 taken together with the nitrogen to which they are attached is oxazolidinonyl or dioxothiazinyl; R 7 is hydrogen, alkyl, R 8 is hydrogen or alkyl; R 9 is hydrogen or alkyl; R 10 is hydrogen or alkyl; or R 9 and R 10 taken together is ethylene, propylene, butylene, or pentylene; R 11 is hydrogen or alkyl; R 12 is hydrogen or alkyl; or R 11 and R 12 taken together with the nitrogen to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl; R 13 is hydrogen or alkyl; R 14 is hydrogen or alkyl; or R 13 and R 14 taken together with the nitrogen to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl; R 15 is alkyl or cycloalkyl; R 16 is hydrogen, halo, alkyl, or alkoxy; R 17 is hydrogen, halo, alkyl, or alkoxy; and Ar 1 is isoxazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, or phenyl, and is substituted with 0-1 halo, alkyl, or phenyl substituents; or a pharmaceutically acceptable salt thereof.